Bill > SB0282

This bill establishes the "Individualized Investigational Treatment Act," which creates a legal framework for patients with life-threatening or severely debilitating illnesses to access personalized, experimental medical treatments. The legislation defines an "eligible patient" as someone who has exhausted conventional FDA-approved treatments and receives a recommendation from their physician for a unique, genetically-tailored treatment, such as gene therapy or personalized vaccines. To access these treatments, patients must provide comprehensive written, informed consent that outlines potential risks, treatment alternatives, and financial responsibilities. The bill protects healthcare providers from professional discipline for recommending these treatments and prevents state officials from blocking patient access. Importantly, the law does not require manufacturers or healthcare facilities to provide these treatments, and it does not mandate that insurance companies cover the costs. The bill also shields manufacturers and healthcare providers from liability if they act in good faith and exercise reasonable care. Patients and their heirs are protected from outstanding debt related to the experimental treatment, and the law takes effect on July 1, 2025, providing a structured approach for patients to explore cutting-edge, personalized medical interventions when traditional treatments have been unsuccessful.

Health and Social Services

https://wapp.capitol.tn.gov/apps/Billinfo/default.aspx?BillNumber=SB0282&ga=114